Loading
Life sciences · Phase 4 Trial
ClinicalTrials.gov · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 4 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06260059). This is a study registration, not published results. Lead sponsor: Anita Saraf. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 40 participants (ESTIMATED). Conditions: Adult Congenital Heart Disease, Heart Failure. Interventions: DRUG: Empagliflozin 10 MG; DRUG: Placebo. Primary outcome measures: Change in Ejection fraction (EF) , Change from baseline in ejection fraction at 1-year; Change in Myocardial characteristics (T1 mapping of cMRI) , Change from baseline in T1 mapping at 1-year; Change in Myocardial characteristics (Global strain on MRI) , Change from baseline of global strain on MRI at 1 year; Change in Myocardial characteristics (Global strain on echocardiogram) , Change from baseline of global strain on echocardiogram at 1 year; Change in functional exercise capacity of participants. , Change from baseline of exercise capacity at 1-year; Number of Participants Hospitalized for Cardiac Reasons or heart transplantation , Cardiac hospitalizations or transplantation at 1 year.; Number of Deaths , Number of deaths at 1 year. Brief summary: The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).